- Lexaria’s patented DehydraTECH(TM) technology provides faster delivery times, increases bioavailability, increases brain absorption, improves drug potency, reduces administration costs, and masks unwanted flavors
- The epilepsy research will compare the FDA-approved Epidiolex(R) to the company’s proprietary DehydraTECH-CBD formulation
- The global cannabidiol (“CBD”) market had an estimated value of $2.7 billion in 2021 and is expected to reach $111.8 billion by 2030, driven by an increase in demand for CBD use in health and wellness industries
Lexaria Bioscience (NASDAQ: LEXX) (NASDAQ: LEXXW), a global innovator in drug delivery platforms, recently announced that the first phase of its epilepsy research program, EPIL-A21-1, has begun. The research program will assess the seizure-inhibiting activity of cannabidiol (“CBD”) administered via the company’s proprietary DehydraTECH(TM) technology, compared to the only FDA-approved CBD-based seizure medication, Epidiolex(R) (https://ibn.fm/uD9Sa). Epidiolex(R) is the first and only FDA CBD medication for the treatment of seizures associated with two rare forms of pediatric epilepsy — Lennox-Gastaut syndrome and Dravet syndrome.
Using DehydraTECH’s advanced drug delivery capabilities, Lexaria hopes to demonstrate superior performance in the research program. The company expects to achieve significant gains in systemic delivery and brain uptake — which have been evidenced and announced from other studies comparing the DehydraTECH 2.0 CBD formulations with concentration-matched controls. Lexaria believes this could improve therapeutic efficacy for multiple conditions of the nervous system, including but not limited to epilepsy.
The EPIL-A21-1 research program contains two main studies to be performed in rodents following the first phase — a pilot animal model that has already begun. The main studies are slated to commence in May/June and involve an acute seizure model induced by electrical stimulation and chemically induced seizure models. Lexaria has chosen these models because they were previously selected by other researchers studying the antiepileptic effects of CBD during the Epidiolex formulation.
The DehydraTECH-CBD test articles needed to commence dosing have already been manufactured and delivered to the third-party laboratory tasked with completing the research program. Lexaria will release updates on the studies occasionally beginning in Q3, 2022.
Lexaria’s DehydraTECH technology is designed for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. Benefits of the DehydraTECH technology include:
- Faster delivery times — subjects begin to feel the effects of the product in minutes
- Increase in bioavailability — the technology is more efficient at delivering products into the bloodstream
- Increased brain absorption — testing suggests that DehydraTECH significantly improves the amount of drug delivered across the blood-brain barrier
- Improved drug potency — more ingested product is made available to the body, requiring lower dosages to achieve the same desired effect
- Reduction in drug administration costs — lower doses translate to lower administration costs
- Masks unwanted taste — the technology eliminates or reduces the need for sweeteners
By leveraging its technology, Lexaria Bioscience can successfully tap into the ever-growing CBD market. The global CBD sector had an estimated value of $2.7 billion for 2021 and is expected to grow at a CAGR of 51% by 2030, reaching a value of $111.8 billion (https://ibn.fm/6sjWu and https://ibn.fm/4LKbw). The increase in demand for CBD use in the health and wellness market is the primary driver of growth. As CBD becomes legal in more regions, it is attracting the attention of e-commerce platforms — with North America dominating the market. The growth can also be attributed to the increased adoption of technology and overall greater investments in research and development opportunities.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
